Genmab A/S (Nasdaq: GMAB) and ProfoundBio, Inc. have officially announced a definitive agreement for Genmab's acquisition of ProfoundBio in an all-cash dea...
“The acquisition of CymaBay brings us a potential best-in-disease therapy that could transform the treatment landscape for people wit...
Isansys Lifecare, led by the visionary Keith Errey, has gained recognition in the global healthcare technology market, particularly through its suc...
Croda International Plc (Croda) and The Access to Advanced Health Institute (AAHI) are pleased to announce the signing of a partnership agreement around in...
Lonza has signed an agreement to acquire the Genentech manufacturing facility in Vacaville (US) from Roche for USD 1.2 billion in cash Vacaville (US) si...
AstraZeneca has announced its definitive agreement to acquire Fusion Pharmaceuticals Inc., a trailblazing clinical-stage biopharmaceutical company speciali...
The deal, valued at up to $1.05 billion, comprises an $800 million upfront payment and an additional $250 million contingent upon r...
Biocon Biologics Limited, a fully integrated global biosimilars company and a subsidiary of Biocon Limited (BSE code: 532523, NSE: BIOCON),...
Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneous...
– Proceeds will be used to complete clinical demonstration trials of the lead candidate drug RNDP-001 for the treatment of Parkinson's di...
Immediately after the effective time of the Acquisition, and before giving effect to the concurrent private placement the former stockholders of Bi...
ICIG acquires production facilities at five locations in Germany and U.S. Purchase price in low triple-digit million euro range Closing expected for mi...
In a bold move, Ricks emphasized the urgency for financial regulators to scrutinize the deal, pointing out Catalent's extensive client base, compri...
The acquisition encompasses key assets such as pelabresib, a promising late-stage BET inhibitor for myelofibrosis (MF), and tulmimetostat, an early-stage i...
© 2024 Biopharma Boardroom. All Rights Reserved.
